Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 60 years of age or older
- People who have been diagnosed with sarcopenia (low muscle mass and/or weakness) according to the 2019 Asian Working Group for Sarcopenia criteria — this means having low muscle mass measured by a bone density scan, AND either a weak handgrip strength OR a slow walking speed (or both)
- People who have been diagnosed with heart failure according to the European Society of Cardiology 2021 guidelines
- People who fully understand the study and its purpose, and are willing to sign a consent form agreeing to take part
Who may not be able to join:
- People who have had a recent acute heart or coronary event within the past 2 days
- People with unstable coronary artery disease (blocked or narrowed heart arteries that are not yet stable)
- People whose heart failure is currently not well controlled (decompensated)
- People with a recent blood clot in the veins or arteries (including the lungs)
- People with active inflammation of the heart muscle, the sac around the heart, or the heart valves
- People with a tear in the wall of the aorta (the main blood vessel from the heart)
- People with severe narrowing of the aortic valve that is causing symptoms
- People who currently have an active infection or fever
- People with dangerous or uncontrolled irregular heart rhythms, including newly developed atrial fibrillation or flutter
- People with an uncontrolled fast resting heart rate (over 120 beats per minute)
- People with a specific type of severe heart conduction problem called third-degree AV block
- People with uncontrolled diabetes
- People who experience a significant drop in blood pressure when standing (more than 20 mmHg), causing symptoms
- People who have had increasing tiredness during exercise, or breathlessness at rest or with activity, in the past 3–5 days
- People who show significant signs of reduced blood flow to the heart even with very light activity
- People who have gained 1.8 kg or more in weight over the past 1–3 days
- People who are currently receiving a continuous or intermittent infusion of a medication called Dobutamine
- People whose blood pressure drops during exercise
- People with the most severe stage of heart failure (classified as NYHA Class IV)
- People with complex irregular heart rhythms at rest or during activity
- People with a resting heart rate of 100 beats per minute or more while lying down
- People with other health conditions that prevent them from doing physical exercise
- People with a severe form of thickened heart muscle that obstructs blood flow (severe obstructive hypertrophic cardiomyopathy)
- People who have taken part in a heart rehabilitation program within the last 6 months
- People who do not agree to participate in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nguyen Dang P Kieu, M.D., University of Medicine and Pharmacy at Ho Chi Minh City
Phone: (+84)984701516
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The change of muscle strength
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.